# Epileptogenesis After Stroke: Current Insights Into Molecular and Structural Mechanisms

## TL;DR

This paper explores how stroke can lead to epilepsy by examining the complex interactions between brain injury and molecular changes, and highlights potential ways to prevent post-stroke epilepsy.

## Contribution

The paper provides a comprehensive overview of the molecular and structural mechanisms of epileptogenesis after stroke and identifies potential biomarkers and therapeutic strategies.

## Key findings

- Epileptogenesis after stroke involves prolonged interactions between structural injury and molecular processes like inflammation and oxidative stress.
- Candidate biomarkers such as lesion topology and early EEG abnormalities may help predict epilepsy risk after stroke.
- Therapeutic approaches targeting inflammation, oxidative stress, and epigenetic changes show promise in preclinical studies.

## Abstract

Stroke is among the most common causes of acquired epilepsy in adults, and post-stroke epilepsy (PSE) is a substantial driver of long-term disability. Epileptogenesis after stroke is not a single event but a prolonged, multi-phase process in which structural injury (neuronal loss, gliosis, blood-brain barrier (BBB) dysfunction, and maladaptive synaptic remodeling) interacts with molecular programs, including excitotoxicity, inflammation, oxidative stress, and epigenetic reprogramming, to create a persistently hyperexcitable network. Recent advances in neuroimaging, electrophysiology, and molecular profiling have yielded a growing set of candidate biomarkers (lesion topology and volume, metabolic and microstructural imaging signatures, early electroencephalographic abnormalities, and blood or CSF-derived proteins and microRNAs). Although none has yet been validated for routine clinical use, a multimodal, longitudinal biomarker strategy could enable risk stratification and serve as a surrogate endpoint for anti-epileptogenic trials. Therapeutic development remains focused largely on seizure suppression, but anti-inflammatory, antioxidant, metabolic-epigenetic, mitochondrial, and neuromodulatory approaches demonstrate promise in preclinical and translational studies. A clearer understanding of how structural damage and molecular signaling interlock over time, paired with pragmatic biomarker frameworks, offers a path toward prevention that may reduce the burden of epilepsy after stroke.